Morgan Thomas

h-index4
2papers
63citations

2 Papers

7.3CEDec 1, 2022
Re-evaluating sample efficiency in de novo molecule generation

Morgan Thomas, Noel M. O'Boyle, Andreas Bender et al.

De novo molecule generation can suffer from data inefficiency; requiring large amounts of training data or many sampled data points to conduct objective optimization. The latter is a particular disadvantage when combining deep generative models with computationally expensive molecule scoring functions (a.k.a. oracles) commonly used in computer-aided drug design. Recent works have therefore focused on methods to improve sample efficiency in the context of de novo molecule drug design, or to benchmark it. In this work, we discuss and adapt a recent sample efficiency benchmark to better reflect realistic goals also with respect to the quality of chemistry generated, which must always be considered in the context of small-molecule drug design; we then re-evaluate all benchmarked generative models. We find that accounting for molecular weight and LogP with respect to the training data, and the diversity of chemistry proposed, re-orders the ranking of generative models. In addition, we benchmark a recently proposed method to improve sample efficiency (Augmented Hill-Climb) and found it ranked top when considering both the sample efficiency and chemistry of molecules generated. Continual improvements in sample efficiency and chemical desirability enable more routine integration of computationally expensive scoring functions on a more realistic timescale.

17.0LGMay 7, 2024Code
ACEGEN: Reinforcement learning of generative chemical agents for drug discovery

Albert Bou, Morgan Thomas, Sebastian Dittert et al.

In recent years, reinforcement learning (RL) has emerged as a valuable tool in drug design, offering the potential to propose and optimize molecules with desired properties. However, striking a balance between capabilities, flexibility, reliability, and efficiency remains challenging due to the complexity of advanced RL algorithms and the significant reliance on specialized code. In this work, we introduce ACEGEN, a comprehensive and streamlined toolkit tailored for generative drug design, built using TorchRL, a modern RL library that offers thoroughly tested reusable components. We validate ACEGEN by benchmarking against other published generative modeling algorithms and show comparable or improved performance. We also show examples of ACEGEN applied in multiple drug discovery case studies. ACEGEN is accessible at \url{https://github.com/acellera/acegen-open} and available for use under the MIT license.